Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

New anticoagulants: A concise review. J Trauma Acute Care Surg 2012 Oct;73(4):983-92

Date

09/15/2012

Pubmed ID

22976421

Pubmed Central ID

PMC4516225

DOI

10.1097/TA.0b013e318265cf9e

Scopus ID

2-s2.0-84867090302   27 Citations

Abstract

During the last 2 years, two new oral anticoagulants, dabigatran and rivaroxaban, have been approved in the United States. Phase II and Phase III clinical trials of dabigatran, rivaroxaban, and apixaban are summarized. Approach to perioperative management depends on the half-life of the medication, risk of surgical bleeding, and the patient's renal function. No reversal agent is available for any of the new oral anticoagulants. Management of bleeding patients is based on local measures and consideration of antifibrinolytic therapy and activated factor VII or prothrombin complex concentrate infusion based on healthy volunteer and animal studies. The new oral anticoagulants provide additional options to prevent venous thromboembolism in patients after orthopedic surgery or stroke in patients with atrial fibrillation but present unique challenges compared to warfarin.

Author List

Baumann Kreuziger LM, Morton CT, Dries DJ

Author

Lisa M. Baumann Kreuziger MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Administration, Oral
Anticoagulants
Atrial Fibrillation
Clinical Trials as Topic
Humans
Orthopedic Procedures
Stroke
Thrombosis